This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2005:126:45-68.

doi: 10.1007/0-387-24361-5_3.

Interferons

Simrit Parmar¹, Leonidas C Platanias

Affiliations

PMID: 16209062
DOI: 10.1007/0-387-24361-5_3

Review

Interferons

Simrit Parmar et al. Cancer Treat Res. 2005.

. 2005:126:45-68.

doi: 10.1007/0-387-24361-5_3.

Authors

Simrit Parmar¹, Leonidas C Platanias

Affiliation

¹ Robert H Lurie Comprehensive Cancer Center, Division of Hematology-Onocology, Northwestern University Medical School, Chicago, IL, USA.

PMID: 16209062
DOI: 10.1007/0-387-24361-5_3

No abstract available

PubMed Disclaimer

Similar articles

Interferons: laboratory to clinic investigations.
Platanias LC. Platanias LC. Curr Opin Oncol. 1995 Nov;7(6):560-5. Curr Opin Oncol. 1995. PMID: 8547406 Review.
Utility of interferons in clinical radiotherapy.
Mossman KL, Hill LT, Dritschilo A. Mossman KL, et al. J Natl Med Assoc. 1982 Nov;74(11):1083-7. J Natl Med Assoc. 1982. PMID: 6184481 Free PMC article.
Molecular alterations of interferons.
Stewart WE 2nd, Lin L, Chudzio T, Wiranowska-Stewart M. Stewart WE 2nd, et al. Tex Rep Biol Med. 1977;35:193-7. Tex Rep Biol Med. 1977. PMID: 358448 Review.
Interferons: rationale for clinical trials in neoplastic disease.
Borden EC. Borden EC. Ann Intern Med. 1979 Sep;91(3):472-9. doi: 10.7326/0003-4819-91-3-472. Ann Intern Med. 1979. PMID: 382941 Review.
Interferons and their clinical value.
Tyrrell DA. Tyrrell DA. Rev Infect Dis. 1987 Mar-Apr;9(2):243-9. doi: 10.1093/clinids/9.2.243. Rev Infect Dis. 1987. PMID: 2438740 Review.

See all similar articles

Cited by

Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.
Hayashi T, Shimamura Y, Saegusa T, Horiuchi A, Kobayashi Y, Hiraoka N, Kanai Y, Aburatani H, Sano K, Konishi I. Hayashi T, et al. Gene Regul Syst Bio. 2008 Jul 22;2:297-305. doi: 10.4137/grsb.s470. Gene Regul Syst Bio. 2008. PMID: 19787091 Free PMC article.
The crosstalk between β-catenin signaling and type I, type II and type III interferons in lung cancer cells.
Bai M, Li W, Yu N, Zhang H, Long F, Zeng A. Bai M, et al. Am J Transl Res. 2017 Jun 15;9(6):2788-2797. eCollection 2017. Am J Transl Res. 2017. PMID: 28670369 Free PMC article.
Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.
Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kasai M, Ichimura T, Sudo T, Tagawa Y, Nishimura R, Ishiko O, Kanai Y, Yaegashi N, Aburatani H, Shiozawa T, Konishi I. Hayashi T, et al. Sci Rep. 2011;1:180. doi: 10.1038/srep00180. Epub 2011 Dec 5. Sci Rep. 2011. PMID: 22355695 Free PMC article.
High levels of β-catenin promote IFNγ-induced apoptosis in hepatocellular carcinoma cells.
Li W, Tong H, Huang X, Wang W, Wu H, Lin S. Li W, et al. Oncol Lett. 2012 Nov;4(5):1092-1096. doi: 10.3892/ol.2012.844. Epub 2012 Aug 6. Oncol Lett. 2012. PMID: 23162658 Free PMC article.
Comparison of the regulation of β-catenin signaling by type I, type II and type III interferons in hepatocellular carcinoma cells.
Li W, Huang X, Tong H, Wang Y, Zhang T, Wang W, Dai L, Li T, Lin S, Wu H. Li W, et al. PLoS One. 2012;7(10):e47040. doi: 10.1371/journal.pone.0047040. Epub 2012 Oct 4. PLoS One. 2012. PMID: 23056571 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database